Abstract 5097
Background
The aim of this study was to assess the efficacy and safety of afatinib, an epidermal growth factor receptor (EGFR) tyrosin kinase inhibitor (TKI), for elderly Japanese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).
Methods
NEJ027 was single-arm, multicenter, open-label phase II study of first-line afatinib monotherapy. Patients aged 75 or older with stage IIIB/IV or recurrent non-squamous NSCLC harboring EGFR mutations were enrolled. The patients received afatinib at a start dose of 40mg/day until disease progression or unacceptable toxicity. The primary endpoint was overall response rate (ORR), and the secondary endpoints were disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and safety profile.
Results
Between January 28, 2016, and September 14, 2017, a total of 38 patients with a median age of 77 years (range, 75-91) were enrolled (15 males; 21 Eastern Cooperative Oncology Group performance status 0; all adenocarcinoma; 23 EGFR exon 19 deletion mutation) in safety analysis and 37 in the full analysis set. The ORR was 75.7% (95% confidence interval: CI 61.9-89.5) and DCR was 89.2%. The median PFS was 14.3 months (95% CI 9.9-not reached). The common grade 3 or 4 adverse events were diarrhea (10 [26.3%]), stomatitis (5 [13.2%]), rash (2 [5.3%]), appetite loss (5 [13.2%]), nail abnormality (4 [10.5%]) and pneumonitis (2 [5.3%]). 30 patients (78.9%) required 1 step or more dose reduction.
Conclusions
Although the percentage of patients requiring dose reduction seemed relatively higher than that in previous studies, first-line afatinib at a start dose of 40mg/day was found to be well-tolerated by dose adjustment and effective in elderly patients with advanced non-squamous NSCLC harboring EGFR mutations.
Clinical trial identification
UMIN000017050.
Legal entity responsible for the study
North East Japan Study Group.
Funding
Japan Agency for Medical Research and Development.
Editorial Acknowledgement
Disclosure
O. Yamaguchi: Honoraria: Bristol-Myers Squibb, Ono Pharm and AstraZeneca. S. Watanabe: Grants: Boehringer Ingelheim, during the conduct of the study; Grants and personal fees: Boehringer Ingelheim, personal fees: Chugai Pharma, Ono Pharmaceutical, Lilly, AstraZeneca, Taiho Pharmaceutical, Pfizer, Bristol-Myers Squibb and Novartis Pharma. M. Mori: Lecture fees: Boehringer Ingelheim. O. Hataji: Lecture fees: Novartis, Boehringer Ingelheim; Research fundings: Novartis, Boehringer Ingelheim, Kyorin Pharm, Bayer Health Care, Daiichi Sankyo, Glaxo Smith Kline. S. Morita: Corporate-sponsored research: Boehringer Ingelheim; Honorarium: Boehringer Ingelheim. K. Kobayashi: Advisory board: AstraZeneca. A. Gemma: Lecture fee: Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract